Skip to content
MARKETS / NASDAQ / ACRS
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Aclaris Therapeutics, Inc. ACRS

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.8M
▼ 58.2% YoY
$-64.9M
$-47.2M
In brief

What this company does

We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. We are seeking to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our novel product candidates. Our biologics pipeline includes bosakitug (ATI-045), an anti-thymic stromal lymphopoietin (“TSLP”) monoclonal antibody which has unique differentiation demonstrated by its low dissociation rate, long residence time and high potency. We are also advancing ATI-052, a novel bispecific antibody that simultaneously targets both TSLP and interleukin-4 receptor (“IL-4Ra”), which blocks signaling of both IL-4 and IL-13, potentially offering enhanced efficacy through dual pathway inhibition.

Written from the business description in Aclaris Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 7.8M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.8 · Net income -64.9
20M-80M-160M2013201520172019202120232025
Compound annual growth
−35.9%
+3.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−830 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -975.9% · Net -829.6%
-2000%-4000%2013201520172019202120232025
ROE
FY2025 · ROE -50.2%
-50%-100%2013201520172019202120232025

Each USD of equity lost 50 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -47.2
-40M-80M2013201520172019202120232025

Total assetsUSD 160.5M
EquityUSD 103.1M
CashUSD 20.0M
Current ratio3.36×

Equity funds 64% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.00.00.00.00.00.00.0····
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0
Income tax $B··−0.0··−0.0··−0.0····
Net income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.2−0.1−0.1−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.0−0.0−0.0·
EPS, diluted $−0.53−1.71−1.27−1.33−1.60−1.20−3.90−4.03−2.44−2.25−3.79−6.15−6.45
Dividend / sh $·············
Payout %·············
ROE %−50.2−84.5−49.9−44.0−77.3−94.9−113.2−60.3−34.7−36.7−57.3··
Shares out B0.120.110.070.070.060.050.040.040.030.030.020.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 52 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 36 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image